CAMBRIDGE, Mass.--(BUSINESS WIRE)--Millennium: The Takeda Oncology Company today announced that 71 oral and poster presentations featuring VELCADE® (bortezomib) for Injection or the Company’s oncology pipeline molecules will be presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) being held in Chicago, Illinois, June 4-8, 2010. These data include five oral presentations on the use of VELCADE based therapy across a spectrum of multiple myeloma treatment settings.
